Hcw biologics granted fda clearance to evaluate one of the company's lead product candidates in a first-in-human phase 1 clinical trial

Miramar, fla., feb. 03, 2025 (globe newswire) -- hcw biologics inc. (“hcwb” or the “company”) (nasdaq: hcwb), a u.s.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced that it has received clearance of its investigational new drug application (“ind”) from the u.s. food and drug administration (“fda”) to initiate a first-in-human phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, hcw9302, in patients with moderate-to-severe alopecia areata, a common autoimmune disease in humans that currently has no curative fda approved treatments.
HCWB Ratings Summary
HCWB Quant Ranking